Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Erlotinib hydrochloride.

× No keyword cloud information.

41 in total

Review 1. The secret ally: immunostimulation by anticancer drugs.

Authors: Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal: Nat Rev Drug Discov Date: 2012-02-03 Impact factor: 84.694

2. Discovery of JND3229 as a New EGFR^C797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Authors: Xiaoyun Lu; Tao Zhang; Su-Jie Zhu; Qiuju Xun; Lingjiang Tong; Xianglong Hu; Yan Li; Shingpan Chan; Yi Su; Yiming Sun; Yi Chen; Jian Ding; Cai-Hong Yun; Hua Xie; Ke Ding
Journal: ACS Med Chem Lett Date: 2018-10-08 Impact factor: 4.345

3. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.

Authors: Xu Zhang; Tapan Maity; Manoj K Kashyap; Mukesh Bansal; Abhilash Venugopalan; Sahib Singh; Shivangi Awasthi; Arivusudar Marimuthu; Harrys Kishore Charles Jacob; Natalya Belkina; Stephanie Pitts; Constance M Cultraro; Shaojian Gao; Guldal Kirkali; Romi Biswas; Raghothama Chaerkady; Andrea Califano; Akhilesh Pandey; Udayan Guha
Journal: Mol Cell Proteomics Date: 2017-03-22 Impact factor: 5.911

4. EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.

Authors: C Wertheimer; R Liegl; M Kernt; W Mayer; D Docheva; A Kampik; K H Eibl-Lindner
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-01-18 Impact factor: 3.117

5. Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors.

Authors: Giovanni Marzaro; Antonio Coluccia; Alessandro Ferrarese; Paola Brun; Ignazio Castagliuolo; Maria Teresa Conconi; Giuseppe La Regina; Ruoli Bai; Romano Silvestri; Ernest Hamel; Adriana Chilin
Journal: J Med Chem Date: 2014-05-14 Impact factor: 7.446

6. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Authors: Bryan T Mott; Cordelle Tanega; Min Shen; David J Maloney; Paul Shinn; William Leister; Juan J Marugan; James Inglese; Christopher P Austin; Tom Misteli; Douglas S Auld; Craig J Thomas
Journal: Bioorg Med Chem Lett Date: 2009-10-03 Impact factor: 2.823

7. Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.

Authors: Koh Furugaki; Toshiki Iwai; Kumiko Kondoh; Yoichiro Moriya; Kazushige Mori
Journal: Oncol Lett Date: 2010-03-01 Impact factor: 2.967

8. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Authors: Ashok Rakhit; Michael P Pantze; Scott Fettner; Hannah M Jones; Jean-Eric Charoin; Myriam Riek; Bert L Lum; Marta Hamilton
Journal: Eur J Clin Pharmacol Date: 2007-11-14 Impact factor: 2.953

9. Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.

Authors: Rachid Skouta; Miki Hayano; Kenichi Shimada; Brent R Stockwell
Journal: Bioorg Med Chem Lett Date: 2012-06-30 Impact factor: 2.823

10. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.

Authors: Li-Jun Yang; Jun Zou; Huan-Zhang Xie; Lin-Li Li; Yu-Quan Wei; Sheng-Yong Yang
Journal: PLoS One Date: 2009-12-24 Impact factor: 3.240